Overview

Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2023-10-31

Target enrollment:

Participant gender:

Summary

to assess the safety,tolerability, pharmacokinetic,pharmacodynamics and efficacy of KY100001 in patients with advanced solid tumors

Phase:

Phase 1

Details

Lead Sponsor:

Kunming Pharmaceuticals, Inc.